Drugs that contain Brimonidine Tartrate
1. List of Alphagan P drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6562873
(Pediatric) | ALLERGAN | Compositions containing therapeutically active components having enhanced solubility |
Jan, 2022
(1 year, 30 days ago) | |
|
US9295641
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 30 days ago) | |
|
US9687443
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 30 days ago) | |
|
US6627210
(Pediatric) | ALLERGAN | Compositions containing α-2-adrenergic agonist components |
Jan, 2022
(1 year, 22 days ago) | |
|
US6673337
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 14 days ago) | |
|
US6641834
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Jan, 2022
(1 year, 12 days ago) | |
| US8858961 | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(6 months from now) | |
|
US8858961
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(1 year, 21 days from now) | |
Market Authorisation Date: 16 March, 2001
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
ALPHAGAN P family patents
15
United States
5
Australia
5
Japan
3
Canada
2
Brazil
2
Mexico
2
China
2
New Zealand
1
Hong Kong
1
Korea, Republic of
1
Poland
1
Israel
1
Hungary
1
Argentina
1
South Africa
1
Russia
1
Norway
1
Taiwan, Province of China
1
European Union
2. List of Lumify drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(7 years from now) | |
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(7 years from now) | |
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIFY family patents
42
United States
4
Canada
4
Japan
4
European Union
2
Spain
1
Slovenia
1
Denmark
1
Korea, Republic of
1
Brazil
1
San Marino
1
Poland
1
Portugal
1
Cyprus
1
Russia
1
Croatia
1
Mexico
3. List of Mirvaso drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(1 year, 3 months from now) | |
| US8231885 | GALDERMA LABS LP | Compounds, formulations, and methods for ameliorating telangiectasis |
May, 2025
(2 years from now) | |
| US8410102 | GALDERMA LABS LP | Methods and compositions for treating or preventing erythema |
May, 2025
(2 years from now) | |
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(2 years from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(2 years from now) | |
| US8513247 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US9861632 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US9861631 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US8513249 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US8053427 | GALDERMA LABS LP | Brimonidine gel composition |
Jun, 2031
(8 years from now) | |
| US8163725 | GALDERMA LABS LP | Gel compositions and methods of use |
Jun, 2031
(8 years from now) | |
| US10201517 | GALDERMA LABS LP | Brimonidine gel compositions and methods of use |
Jun, 2031
(8 years from now) | |
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
MIRVASO family patents
40
United States
10
European Union
9
China
7
Spain
6
Poland
6
Portugal
6
Denmark
5
Korea, Republic of
5
Japan
5
Slovenia
5
Canada
4
Australia
4
Cyprus
4
Mexico
4
Hungary
3
Hong Kong
3
Brazil
3
Israel
3
New Zealand
2
South Africa
2
Russia
2
Croatia
2
Norway
1
Austria
1
RS
1
Lithuania
1
Luxembourg
1
Argentina
1
Singapore
1
San Marino
1
France
4. List of Qoliana drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265117 | SANDOZ INC | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(2 years from now) | |
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic